Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests : Workshop Summary PDF
by Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health
Edited by Adam C. Berger, Steve Olson, Samuel G. Johnson, Sarah H. Beachy
- Information
Description
Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities-pharmaceutical and diagnostic companies-now working in close collaboration.
Information
-
Download Now
- Format:PDF
- Pages:102 pages
- Publisher:National Academies Press
- Publication Date:06/03/2014
- Category:
- ISBN:9780309298223
Other Formats
- EPUB from £30.23
Information
-
Download Now
- Format:PDF
- Pages:102 pages
- Publisher:National Academies Press
- Publication Date:06/03/2014
- Category:
- ISBN:9780309298223